Peptide Labs score history

Score over time

Every entry newest first

1. November 6, 2026Raised from3.72→to3.77(+0.05)

   Lab score recomputed under the published rule on 6 November 2026: lab 1.9 to 2.0.

2. November 2, 2026Raised from3.69→to3.72(+0.03)

   Market medians updated after the 2 November re-checks pricing 5.7 to 5.9.

3. November 1, 2026Lowered from3.70→to3.69(-0.01)

   Market medians updated after Bluum Peptides was added pricing 5.8 to 5.7.

4. October 29, 2026Raised from3.65→to3.70(+0.05)

   Core products recomputed on 29 October 2026 (rule A1b): listings added for newly reviewed vendors made NAD+ a core product in place of CJC-1295, so a missing certificate for each now counts at its new weight: lab 1.8 to 1.9.

5. October 27, 2026Lowered from3.66→to3.65(-0.01)

   Market medians updated after S1Research was added pricing 5.9 to 5.8.

6. October 27, 2026Lowered from3.71→to3.66(-0.05)

   Pricing recomputed on 27 October 2026: listings added for a newly reviewed vendor (Peptide Pro) moved the market median for the same products pricing 6.2 to 5.9.

7. October 26, 2026Raised from3.66→to3.71(+0.05)

   Pricing recomputed on 26 October 2026: a vendor was removed from the directory, which moved the market median for the same products: pricing 5.9 to 6.2.

8. October 23, 2026Lowered from3.69→to3.66(-0.03)

   Pricing recomputed on 23 October 2026 from current listings with the published rule (section E), after listings added or updated since 22 October, including a newly reviewed vendor's, moved the market median for the same products: pricing 6.1 to 5.9.

9. October 22, 2026Raised from3.58→to3.69(+0.11)

   Lab score recalculated on 22 October 2026 under the published core-product rule (A1b): a missing certificate on one of the 15 most widely carried products still counts fully, while on any other product it now counts at half weight, so a broad catalogue is not penalised as much for its breadth. Lab 1.6 to 1.8.

10. October 22, 2026Re-checked, no change (3.58)

    Re-scored on 22 October 2026 under version 2 of our published rules. No score change. The testing gate is now computed from the certificates instead of set by hand: 4 of 19 products have a certificate from a directory laboratory with the key confirmed at the laboratory, fewer than the half required, so the testing cap applies; the cap sits above the weighted score, so it does not lower it.

11. October 22, 2026Raised from3.29→to3.58(+0.29)

    Re-scored on 22 October 2026 under our published rubric for shipping, pricing, operating history and transparency, applied to every vendor the same day: prices re-read from the vendor's site and matched by milligrams per vial, operating history from the earliest dated evidence of the business, and policies scored item by item. shipping and refunds 5.5 to 8.0, pricing 7.3 to 6.1, transparency 2.0 to 1.5.

12. October 21, 2026Lowered from3.50→to3.29(-0.21)

    Lab 2.0 to 1.6, correcting the 18 October 2026 figure. Four of the 19 products we list carry their own Kovera certificate, confirmed at the laboratory; three score 8 and tesamorelin 6.5 under our rubric, and the other 15 count as zero, which gives 1.6.

13. October 18, 2026Raised from3.11→to3.50(+0.39)

    Re-audit, read through a customer account because the whole catalog is now behind registration. Lab rises from 0 to 2.0 and testing is now counted as third-party: eight Kovera reports from May 2026 were verified at the laboratory, but they cover a small part of a catalog of more than sixty products, and one blend report is presented for standalone BPC-157 and TB-500. Shipping falls from 7.2 to 5.5 (no refunds or returns). Pricing falls from 8.5 to 7.3 on live prices near the market median. Tenure falls from 3.3 to 2.2 (domain registered August 2025). Transparency falls from 4.6 to 2.0: no company or address is published.